CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 115 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,566,393 | -16.1% | 507,471 | -38.4% | 0.00% | 0.0% |
Q2 2023 | $9,019,506 | +4.2% | 823,699 | -17.0% | 0.00% | 0.0% |
Q1 2023 | $8,653,562 | +405.4% | 992,381 | +263.4% | 0.00% | – |
Q4 2022 | $1,712,206 | +124.4% | 273,079 | +25.4% | 0.00% | – |
Q3 2022 | $763,000 | -44.2% | 217,702 | -53.0% | 0.00% | – |
Q2 2022 | $1,367,000 | +252.3% | 463,451 | +272.2% | 0.00% | – |
Q1 2022 | $388,000 | +3.7% | 124,519 | +12.4% | 0.00% | – |
Q4 2021 | $374,000 | -43.0% | 110,799 | -38.4% | 0.00% | – |
Q3 2021 | $656,000 | -70.3% | 179,868 | -64.5% | 0.00% | – |
Q2 2021 | $2,210,000 | +319.4% | 507,083 | +336.5% | 0.00% | – |
Q1 2021 | $527,000 | +21.1% | 116,176 | +53.5% | 0.00% | – |
Q4 2020 | $435,000 | -4.6% | 75,692 | +20.0% | 0.00% | – |
Q3 2020 | $456,000 | -53.5% | 63,057 | -77.6% | 0.00% | – |
Q2 2020 | $981,000 | +322.8% | 281,087 | +79.6% | 0.00% | – |
Q1 2020 | $232,000 | -95.1% | 156,514 | -93.6% | 0.00% | -100.0% |
Q4 2019 | $4,765,000 | +119.6% | 2,431,460 | +474.0% | 0.00% | 0.0% |
Q3 2019 | $2,170,000 | +4722.2% | 423,611 | +6486.0% | 0.00% | – |
Q2 2019 | $45,000 | -89.6% | 6,432 | -80.2% | 0.00% | – |
Q1 2019 | $432,000 | -82.3% | 32,478 | -89.5% | 0.00% | -100.0% |
Q4 2018 | $2,441,000 | +85.6% | 310,124 | +161.3% | 0.00% | – |
Q3 2018 | $1,315,000 | -35.1% | 118,700 | -21.4% | 0.00% | -100.0% |
Q2 2018 | $2,027,000 | +250.1% | 151,050 | +239.1% | 0.00% | – |
Q1 2018 | $579,000 | +16.0% | 44,548 | -17.9% | 0.00% | – |
Q4 2017 | $499,000 | +8.5% | 54,272 | -4.8% | 0.00% | – |
Q3 2017 | $460,000 | +280.2% | 57,024 | +170.5% | 0.00% | – |
Q2 2017 | $121,000 | -14.8% | 21,078 | -35.6% | 0.00% | – |
Q1 2017 | $142,000 | +1675.0% | 32,728 | +652.4% | 0.00% | – |
Q4 2016 | $8,000 | +166.7% | 4,350 | +210.7% | 0.00% | – |
Q3 2016 | $3,000 | +200.0% | 1,400 | +366.7% | 0.00% | – |
Q2 2016 | $1,000 | – | 300 | +100.0% | 0.00% | – |
Q1 2016 | $0 | -100.0% | 150 | -94.2% | 0.00% | – |
Q3 2015 | $5,000 | -28.6% | 2,568 | 0.0% | 0.00% | – |
Q2 2015 | $7,000 | -98.9% | 2,568 | -97.1% | 0.00% | – |
Q1 2015 | $610,000 | +222.8% | 88,171 | +357.8% | 0.00% | – |
Q4 2014 | $189,000 | – | 19,259 | +76936.0% | 0.00% | – |
Q3 2014 | $0 | – | 25 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |